Skip to main content
Top
Published in: Annals of Surgical Oncology 8/2014

01-08-2014 | Breast Oncology

The Pregnant Breast Cancer Patient: Are We Failing Our Most Vulnerable Population?

Authors: Marie Catherine Lee, MD, FACS, Christine Laronga, MD, FACS

Published in: Annals of Surgical Oncology | Issue 8/2014

Login to get access

Excerpt

Breast cancer in the premenopausal population is uncommon, and breast cancer diagnosed in pregnancy is a frankly rare event, occurring in approximately 1/3,000 breast cancer cases annually. Considering the recent national and international trend of deferred childbearing, the incidence of breast cancer in pregnancy is likely to remain the same or increase in the coming years. Happily, breast cancer patients have been the beneficiaries of cutting edge cancer therapy in all modalities. These advances have not only significantly improved quality of life, they have also had a marked effect on the longevity of women diagnosed with breast cancer, even those presenting with late-stage disease. Thus, it is our responsibility as surgeons and oncologists to offer this special population the best that modern medicine has on hand. However, we frequently fall short of this goal when treating the pregnant breast cancer patient due to a lack of knowledge, the paucity of data, as well as fear for the potential current and future effects of therapy on the fetus. …
Literature
2.
go back to reference Cardonick EMD, et al. Breast cancer during pregnancy: maternal and fetal outcomes. Cancer J. 2010;16(1):76–82.PubMedCrossRef Cardonick EMD, et al. Breast cancer during pregnancy: maternal and fetal outcomes. Cancer J. 2010;16(1):76–82.PubMedCrossRef
3.
go back to reference Lee MC, et al. Consequences of axillary ultrasound in patients with T2 or greater invasive breast cancers. Ann Surg Oncol. 2011;18(1):72–77.PubMedCrossRef Lee MC, et al. Consequences of axillary ultrasound in patients with T2 or greater invasive breast cancers. Ann Surg Oncol. 2011;18(1):72–77.PubMedCrossRef
4.
go back to reference Gentilini O, et al. Sentinel lymph node biopsy in pregnant patients with breast cancer. Eur J Nucl Med Mol Imaging. 2010;37(1):78–83.PubMedCrossRef Gentilini O, et al. Sentinel lymph node biopsy in pregnant patients with breast cancer. Eur J Nucl Med Mol Imaging. 2010;37(1):78–83.PubMedCrossRef
5.
go back to reference Gentilini O, et al. Safety of sentinel node biopsy in pregnant patients with breast cancer. Ann Oncol. 2004;15(9):1348–1351.PubMedCrossRef Gentilini O, et al. Safety of sentinel node biopsy in pregnant patients with breast cancer. Ann Oncol. 2004;15(9):1348–1351.PubMedCrossRef
6.
go back to reference Keleher A, et al. The safety of lymphatic mapping in pregnant breast cancer patients using Tc-99m sulfur colloid. Breast J. 2004;10(6):492–495.PubMedCrossRef Keleher A, et al. The safety of lymphatic mapping in pregnant breast cancer patients using Tc-99m sulfur colloid. Breast J. 2004;10(6):492–495.PubMedCrossRef
7.
go back to reference Spanheimer P, et al. Measurement of uterine radiation exposure from lymphoscintigraphy indicates safety of sentinel lymph node biopsy during pregnancy. Ann Surg Oncol. 2009;16(5):1143–1147.PubMedCrossRef Spanheimer P, et al. Measurement of uterine radiation exposure from lymphoscintigraphy indicates safety of sentinel lymph node biopsy during pregnancy. Ann Surg Oncol. 2009;16(5):1143–1147.PubMedCrossRef
8.
go back to reference Pandit-Taskar N, et al. Organ and fetal absorbed dose estimates from 99mTc-sulfur colloid lymphoscintigraphy and sentinel node localization in breast cancer patients. J Nucl Med. 2006;47(7):1202–1208.PubMed Pandit-Taskar N, et al. Organ and fetal absorbed dose estimates from 99mTc-sulfur colloid lymphoscintigraphy and sentinel node localization in breast cancer patients. J Nucl Med. 2006;47(7):1202–1208.PubMed
9.
go back to reference Pruthi S, et al. Pharmacokinetics of methylene blue dye for lymphatic mapping in breast cancer-implications for use in pregnancy. Am J Surg. 2011;201(1):70–75.PubMedCrossRef Pruthi S, et al. Pharmacokinetics of methylene blue dye for lymphatic mapping in breast cancer-implications for use in pregnancy. Am J Surg. 2011;201(1):70–75.PubMedCrossRef
10.
go back to reference Khera SY, et al. Pregnancy-associated breast cancer patients can safely undergo lymphatic mapping. Breast J. 2008;14(3):250–254.PubMedCrossRef Khera SY, et al. Pregnancy-associated breast cancer patients can safely undergo lymphatic mapping. Breast J. 2008;14(3):250–254.PubMedCrossRef
11.
go back to reference Carlson R, et al. NCCN clinical practice guidelines in oncology: breast cancer. V.2.2010. NCCN; 2010. Carlson R, et al. NCCN clinical practice guidelines in oncology: breast cancer. V.2.2010. NCCN; 2010.
12.
go back to reference Lyman GH, et al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. Epub; 2014. Lyman GH, et al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. Epub; 2014.
Metadata
Title
The Pregnant Breast Cancer Patient: Are We Failing Our Most Vulnerable Population?
Authors
Marie Catherine Lee, MD, FACS
Christine Laronga, MD, FACS
Publication date
01-08-2014
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 8/2014
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-014-3720-8

Other articles of this Issue 8/2014

Annals of Surgical Oncology 8/2014 Go to the issue